Richard A Glennon

[ Back to the Chemistry Archive ]

Publications

1. Coburn, R. A.; Carapellotti, R. A.; Glennon, R. A., A PPP p-SCF Variable Integral Study of Mesoionic Analogs Based on Six Membered Ring Mesoionic Systems. J. Heterocyclic Chem. 1973, 10, 479.

2. Coburn, R. A.; Glennon, R. A., Synthesis and Properties of Mesoionic Thiazolo[3,2-a]pyrimidin-5,7-diones; J. Heterocyclic Chem. 1973, 10, 487.

3. Coburn, R. A.; Glennon, R. A., Synthesis and in vitro Antibacterial Properties of Mesoionic Thiazolo[3,2-a] pyrimidin-5,7-diones and Mesoionic 1,3,4- Thiadiazolo[3,2a]pyrimidin-5,7-diones; J.Pharm.Sci. 1973, 62, 1785.

4. Coburn, R. A.; Bhooshan, B.; Glennon, R. A., The Preparation of 2-Alkylamino-1,3,4-thiadiazoles. J. Org. Chem. 1973, 38, 3947.

5. Coburn, R. A.; Glennon, R. A.; Chmielewicz, Z., In vitro Antibacterial Activity of Mesoionic 1,3,4-Thiadiazolo [3,2a]pyrimidin-5,7-diones; J. Med. Chem. 1974, 17, 1025.

6. Glennon, R. A., A Quantum Chemical Investigation of the p Electronic Structure of the Hallucinogenic N,N-Dimethyltryptamines; Res. Commun. Chem. Path. Pharmacol. 1974, 9, 185.

7. Glennon, R. A.; Von Strandtmann, M., Cyclodehydration of N-Heteroarylcarbamoylmethylbenzamides; J. Heterocyclic Chem. 1975, 12, 135.

8. Glennon, R. A.; Gessner, P. K., The Electronic and Serotonin Receptor Binding Affinity properties of N,N-Dimethyltryptamine Analogs; Res. Commun. Chem. Path. Pharmacol. 1977, 18, 453.

9. Kier, L. B.; Glennon, R. A., Psychotomimetic Phenalkylamines as Serotonin Agonists: An SAR Analysis; Life Sciences 1978, 20, 1589.

10. Glennon, R. A.; Martin, B.; Johnson, K.; End, D., 7,N,N-Trimethyltryptamine: A Selective Inhibitor of Synaptosomal Serotonin Uptake; Res. Commun. Chem., Path. Pharmacol. 1978, 19, 161.

11. Glennon, R. A.; Liebowitz, S. M.; Mack, E. C., Serotonin Receptor Binding Affinities of Several Hallucinogenic Phenalkylamine and N,N-Dimethyltryptamine Analogs. J. Med. Chem. 1978, 21, 822.

12. Glennon, R. A.; Kier, L. B., LSD Analogs as Serotonin Antagonists: A Molecular Connectivity SAR Analysis; Eur. J. Med. Chem. 1978, 13, 219.

13. Glennon, R. A.; Rogers, M. E.; Bass, R. G.; Ryan, S. B., Mesoionic Xanthine Analogs as Inhibitors of Cyclic AMP Phosphodiesterase; J. Pharm. Sci. 1978, 67, 1762.

14. Watson,H.; Glennon, R.A., Common Drug Interactions; Anesthesia Update Series 1978, 6, 1.

15. Glennon, R. A.; Kier, L. B.; Shulgin, A. T., A Molecular Connectivity Analysis of Mescaline Analogs; J. Pharm. Sci. 1979, 68, 906.

16. Glennon, R. A.; Rosecrans, J. A.; Young, R.; Gaines, J., Hallucinogens as Discriminative Stimuli: Generalization of a 5-Methoxy DMT stimulus with DOM. Life Sciences 1979, 24, 993.

17. Glennon, R. A.; Bass, R. G.; Schubert, E., Alkylation of Thiazolo[3,2-a]pyrimidin-5,7-diones; J. Heterocyclic Chem. 1979, 16, 903.

18. Glennon, R. A., The Effect of Chirality on Serotonin Receptor Affinity; Life Sciences, 1979, 24, 1487.

19. Glennon, R. A., A Similarity Between Rat Fundus Serotonin Receptors and Brain Serotonin Binding Sites; Res. Commun. Psychol. Psychiat. Behav., 1979, 4, 333.

20. Glennon, R. A.; Gessner, P. K., Serotonin Receptor Affinities of Tryptamine Analogs; J. Med. Chem. 1979, 22, 428.

21. Glennon, R. A.; Gessner, P. K.; Godse, D.; Kline, B., Bufotenine Esters, J. Med. Chem. 1979, 22, 1414.

22. Rosecrans, J. A.; Glennon, R. A., Drug Induced Cues in Studing Mechanisms of Drug Action. Neuropharmacology 1979, 18, 981.

23. Glennon, R. A.; Rogers, M. E.; El-Said, M. K., Imidazo[1,2a]-pyrimidines and 1,2,4-Triazolo[1,5-a] pyrimidines: Two new examples of mesoionic xanthine analogs. J. Heterocyclic Chem. 1980, 17, 337.

24. Glennon, R. A.; Liebowitz, S. M.; Anderson III, G. M., Serotonin Receptor Affinities of Psychoactive Phenalkylamine Analogs; J. Med. Chem. 1980, 23, 294.

25. Minnema, D.; Krynock, G.; Young, R.; Glennon, R. A.; Rosecrans, J. A., Role of Dorsal Raphe Neurons to the Ability of LSD to act as a Discriminative Stimulus. J. Alcohol Drug Abuse 1980, 1, 29.

26. Glennon, R. A.; Young, R.; Rosecrans, J. A.; Kallman, M. J., Hallucinogenic Agents as Discriminative Stimuli: A Correlation with Serotonin Receptor Affinities. Psychopharmacology 1980, 68, 155.

27. Glennon, R. A.; Liebowitz, S. M.; Doot, D. L.; Rosecrans, J. A., Demethyl Analogues of Psychoactive Methoxy phenylisopropylamines: Synthesis and Serotonin Receptor Affinities; J. Med. Chem. 1980, 23, 990.

28. Glennon, R. A.; Schubert, E.; Jacyno, J. M., Studies on Several 7-Substituted N,N-Dimethyltryptamines; J. Med. Chem. 1980, 23, 1222.

29. Glennon, R. A.; Doot, D. L.; Young, R., DOM and Related 2,5-Dimethoxy-4-alkylphenylisopropylamines: Behavioral and Serotonin Receptor Properties; Pharmacol. Biochem. Behav. 1981, 14, 287.

30. Glennon, R. A.; Rogers, M. E.; Smith, J. D.; El-Said, M. K.; Egle, J. L., Mesoionic Xanthine Analogues: Phosphodiesterase Inhibitory and Hypotensive Activity, J. Med. Chem. 1981, 24, 658.

31. Glennon, R. A.; Salley, J. J.; Steinsland, O. S.; Nelson, S., Synthesis and Evaluation of Novel Alkylpiperazines as Potential Dopamine Antagonists; J. Med. Chem. 1981, 24, 678.

32. Glennon, R. A.; Gaines, J. J.; Rogers, M. E., Benz-fused Mesoionic Xanthine Analogues as Inhibitors of Cyclic-AMP Phosphodiesterase. J. Med. Chem. 1981, 24, 766.

33. Rogers, M. E.; Glennon, R. A.; Smith, J. D.; Boots, M. R.; Nanavati, N.; Maconaughey, J. E.; Aub, D.; Thomas, S.; Bass, R. G.; Mbagwu, G., Mesoionic Purinone Analogues as Inhibitors of Cyclic-AMP Phosphodiesterase: A Comparison of Several Ring Systems; J. Med. Chem. 1981, 24, 1284.

34. Glennon, R. A.; Showalter, D., The Effects of Cathinone and Several Related Derivatives on Locomotor Activity; Res. Commun. Subst. Abuse 1981, 2, 186.

35. Glennon, R. A.; Rosecrans, J. A., Speculations on the Mechanism of Action of Hallucinogenic Indolealkylamines; Neursci. Biobehav. Rev. 1981, 5, 197.

36. Young, R.; Glennon, R. A.; Rosecrans, J. A., Discriminative Stimulus Properties of the Hallucinogenic Agent DOM; Commun. Psychopharmacol. 1981, 4, 501.

37. Glennon, R. A., Serotonin Receptor Interactions of Harmaline and Several Related-Carbolines; Life Sciences 1981, 29, 861.

38. Glennon, R. A.; Schubert, E.; Bass, R. G., Synthesis of Mesoionic Xanthine Nucleosides, Tetrahedron Lett. 1981, 29, 2753.

39. Domelsmith, L. N.; Eaton, T. A.; Houk, K. N.; Anderson, G. M.; Glennon, R. A.; Shulgin, A.T.; Castagnoli, N.; Kollman, P. A., Relationship Between Physical Properties and Pharmacological Actions of Amphetamine Analogues. J. Med. Chem. 1981, 24, 1414.

40. Glennon, R. A.; Rosecrans, J. A.; Young, R., Behavioral Properties of Psychoactive Phenylisopropylamines. Eur. J. Pharmacol. 1981, 76, 353.

41. Glennon, R. A.; Young, R.; Benington, F.; Morin, R. D., Hallucinogens as Discriminative Stimuli: A Comparison of 4-OMe DMT and 5-OMe DMT with their Methylthio Counterparts. Life Sciences 1982, 30, 465.

42. Glennon, R. A.; Jacyno, J. M.; Salley, J. J., 2,3-Dihydro and Carbocyclic Analogues of Tryptamines: Interaction with Serotonin Receptors. J. Med. Chem. 1982, 25, 68.

43. Glennon, R. A.; Rosecrans, J. A.; Young, R., Discriminative Stimulus Properties of DOM and Several Molecular Modifications. Pharmacol. Biochem. Behav. 1982, 16, 553.

44. Glennon, R. A.; Young, R.; Rosecrans, J. A., A Comparison of the Behavioral Effects of DOM Homologs. Pharmacol. Biochem. Behav. 1982, 16, 557.

45. Glennon, R. A.; Liebowitz, S. M., Serotonin Receptor Affinity of Cathinone Analogues. J. Med. Chem. 1982, 25, 393.

46. Young, R.; Rosecrans, J. A.; Glennon, R. A., Comparative Discriminative Stimulus Effects of 5-Methoxy-N,N-dimethyltryptamine and LSD. Life Sciences 1982, 30, 2057.

47. Glennon, R. A.; Young, R.; Rosecrans, J. A.; Anderson, G. M., Discriminative Stimulus Properties of MDA Analogs. Biol. Psychiat. 1982, 17, 807.

48. Salley, J. J.; Glennon, R. A., Studies on Simplified Ergoline Derivatives. A General Six-step Synthesis of Phenyl- Substituted 4-Methyl-3,4a,5,6,10b-hexahydrobenzo[f]quinolin-1(2H)-one Analogs. J. Heterocyclic Chem. 1982, 19, 545.

49. Glennon, R. A.; Young, R., A Comparison of the Behavioral Properties of Di- and Tri-methoxyphenylisopropyl amines. Pharmacol. Biochem. Behav. 1982, 17, 603.

50. Glennon, R. A.; Young, R.; Benington, F.; Morin, R. D., The Behavioral and Serotonin Receptor Properties of 4-Substituted Derivatives of the Hallucinogen 1-(2,5-Dimethoxyphen-yl)-2-aminopropane. J. Med. Chem. 1982, 25, 1163.

51. Glennon, R. A.; Rosecrans, J. A., Indolealkylamine and Phenalkylamine Hallucinogens: A Brief Overview. Neurosci. Biobehav. Rev. 1982, 6, 489.

52. Lund, M. Q.; Kier, L. B.; Glennon, R. A.; Egle, J. L., Preliminary Studies of mesoionic 3-(substituted aryl) pseudo oxatriazoles as potential antihypertensive agents. J. Med. Chem. 1982, 25, 1503.

53. Kline, T.B.; Benington, F.; Morin, R.D.; Beaton, J.M.; Glennon, R.A.; Domelsmith, L.; Houk, K.N.; Rozeboom, M.D., Structure-activity relationships for hallucinogenic N,N- dialkyltryptamines: Photoelectron spectra and 5-HT receptor affinities of methylthio and methylenedioxy derivatives. J. Med. Chem. 1982, 25, 1381.

54. Glennon, R. A.; Young, R.; Jacyno, J. M., Indolealkylamine and Phenalkylamine Hallucinogens: Effect of a-Methyl and N-Methyl Substituents on Behavioral Activity. Biochem. Pharmacol. 1983, 32, 1267.

55. Glennon, R. A.; Young, R.; Jacyno, J. M.; Slusher, R. M.; Rosecrans, J. A., DOM-Stimulus Generalization to LSD and other Hallucinogenic Indolealkylamines. Eur. J. Pharmacol. 1983, 86, 453.

56. Glennon, R. A.; Jacyno, J. M.; Young, R., A Comparison of the Behavioral Properties of (±)-, (+)- and (-)-5-Methoxy-a-methyltryptamine. Biol. Psychiat. 1983, 18, 493.

57. Young, R.; Rosecrans, J. A.; Glennon, R. A., Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine and Dose-Dependent Antagonism by BC-105. Psychopharmacology 1983, 80, 156.

58. Schubert, E. M.; Bass, R. G.; Glennon, R. A., Synthesis of Mesoionic Xanthine Nucleosides. Nucleosides/ Nucleotides 1983, 2, 127.

59. Glennon, R. A.; Rosecrans, J. A.; Young, R., Drug-induced Discrimination: A description of the Paradigm and a Review of its Specific Application to the Study of Hallucinogenic Agents. Med. Res. Rev. 1983, 3, 289.

60. Glennon, R. A.; Young, R.; Rosecrans, J. A., Antagonism of the Effects of the Hallucinogen DOM and the Purported Serotonin Agonist Quipazine by 5-HT2 Antagonists. Europ. J. Pharmacol. 1983, 91, 189.

61. Glennon, R. A.; Young, R.; Jacyno, J. M.; Nelson, D. Synthesis and Evaluation of a Novel Series of N,N-Di- methylisotryptamines. J. Med. Chem. 1984, 27, 41.

62. Mbagwu, G.; Bass, R. G.; Glennon, R. A., Carbon-13 Nuclear Magnetic Resonance Spectra of some Mesoionic Xanthine Analogs. Org. Mag. Res. 1983, 21, 527.

63. Glennon, R. A.; Young, R., MDA: A Psychoactive Agent with Dual Stimulus Effects. Life Sci. 1984, 34, 379.

64. Glennon, R. A.; Young, R., Further Investigation of the Discriminative Stimulus Properties of MDA. Pharmacol. Biochem. Behav. 1984, 20, 501.

65. Wood, P. L.; Pilapil, C.; LaFaille, F.; Nair, N. P.; Glennon, R. A., Unique [3H]Tryptamine Binding Sites in Rat Brain: Distribution and Pharmacology. Arch. Int. Pharmacodyn. 1984, 268, 194.

66. Glennon, R. A.; Young, R.; Soine, W., 1-(2,3-Methylenedioxyphenyl)-2-aminopropane: A Preliminary Investigation. Gen. Pharmacol. 1984, 15, 361.

67. Aceto, M.; Rosecrans, J. A.; Young, R.; Glennon, R. A., Similarity Between (+)-Amphetamine and Amfonelic Acid. Pharmacol. Biochem. Behav. 1984, 20, 635.

68. Young, R.; Dewey, W. L.; Glennon, R. A., Stereoselective Stimulus Effects of 3-Methylflunitrazepam and Pentobarbital. Life Sci. 1984.

69. Schechter, M. D.; Rosecrans, J. A.: Glennon, R. A., Comparison of the Behavioral Effects of Cathinone, Amphetamine and Apomorphine. Pharmacol. Biochem. Behav. 1984, 20, 181.

70. Glennon, R. A.; Schechter, M. D.; Rosecrans, J. A., Discriminative Stimulus Properties of S(-)- and R(+)-Cathinone, (+)-Cathine, and Several Structural Modifications. Pharmacol. Biochem. Behav. 1984, 21, 1.

71. Glennon, R. A.; Young, R., MDA: An Agent that Produces Stimulus Effects Similar to those of 3,4-DMA, LSD and Cocaine. Europ. J. Pharmacol. l984, 99, 249.

72. Shannon, M.; Battaglia, G.; Glennon, R. A.; Titeler, M., 5-HT1 and 5-HT2 Receptor Binding Properties of Derivatives of the Hallucinogen 1-(2,5-Dimethoxyphenyl)-2-aminopropane. Eur. J. Pharmacol. 1984, 102, 23.

73. Glennon, R. A.; Hauck, A.; McKenney, J. D.; Young, R., Structure-Activity Relationships of Amphetamine Analogs Using Drug Discrimination Methodology. Pharmacol. Biochem. Behav. 1984, 21, 895.

74. Glennon, R. A.; Tejani, S. Mesoionic Nucleosides:Studies on Mesoionic Imidazo[2,1-b]1,3-thiazine Derivatives. Nucleosides/Nucleotides 1984, 3, 389.

75. Glennon, R. A.; Tejani, S.; Padgett, W.; Daly, J. W., Mesoionic Xanthine Analogues as Antagonists of Adenosine Receptors. J. Med. Chem. 1984, 27, 1364.

76. Glennon, R. A.; Titeler, M.; McKenney, J. D., Evidence for 5-HT2 Involvement in the Mechanism of Action of Hallucinogenic Agents. Life Sci. 1984, 35, 2505.

77. Glennon, R. A.; McKenney, J. D.; Young, R., Discriminative Stimulus Properties of the Serotonin Agonist 1-(3-Trifluoromethylphenyl)piperazine (TFMPP). Life Sci. 1984, 35, 1475.

78. Glennon, R. A.; Young, R.; Hauck, A. E., Structure-Activity Studies on Methoxy-Substituted Phenylisopropylamines Using Drug Discrimination Methodology. Pharmacol. Biochem. Behav. 1985, 22, 723.

79. Titeler, M.; Herrick, C.; Lyon, R. A.; McKenney, J. D.; Glennon, R. A. [3H]DOB: A specific radioligand for 5-HT2 receptors. Eur. J. Pharmacol. 1985, 117, 145.

80. Young, R.; Glennon, R. A.; Brase, D.; Dewey, W. L. Potencies of diazepam metabolites in generalizing to the diazepam discriminative stimulus. Life Sci. 1985, 39, 17.

81. Glennon, R. A.; Hauck, A. E. Mechanistic studies on DOM as a discriminative stimulus. Pharmacol. Biochem. Behav. 1985, 23, 937.

82. Schubert, E. M.; Schram, K. H.; Glennon, R. A. Mass spectrometry of modified nucleic acid bases and nucleosides. Class II mesoionic nucleosides and bases derived from thiazolo[3,2-a]pyrimidine-5,7-diones. J. Heterocyclic. Chem. 1985, 22, 889.

83. Schechter, M. D.; Glennon, R. A. Cathinone, cocaine and methamphetamine: Similarity of behavioral effects. Pharmacol. Biochem. Behav.. 1985, 22, 913.

84. Mbagwu, G. O.; Bass, R. G.; Glennon, R. A. Studies of amine-induced ring-opening of some mesoionic xanthines, J. Heterocyclic Chem. 1985, 22, 465.

85. Glennon, R. A.; McKenney, J. D.; Lyon, R. A.; Titeler, M 5-HT1 and 5-HT2 binding characteristic of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs J. Med. Chem. 1986, 29, 194.

86. McKenney, J. D.; Glennon, R. A. TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol. Biochem. Behav. 1986, 24, 43.

87. Lyon, R. A.; Titeler, M.; Mckenney, J. D.; Magee, P. S.; Glennon, R. A. Synthesis and evaluation of phenyl- and benzolypiperazines as potential serotonergic agents. J. Med. Chem. 1986, 29, 630.

88. Young, R.; Glennon, R. A.; Amphetamine and related phenalkylamines as discriminative stimuli: A review of the literature. Med. Res. Rev. 1986, 6, 99.

89. Lyon, R. A.; Glennon, R. A.; Titeler, M. 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 sites. Psychopharmacology 1986, 88, 525.

90. Glennon, R. Discriminative stimulus properties of the 5-HT1A agonist 8-OH DPAT. Life Sci. 1986, 39, 825.

91. Glennon, R. A. Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Pharmacol. Biochem. Behav. 1986, 25, 135.

92. Kalix, P.; Glennon, R. A. Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem. Pharmacol. 1986, 35, 3015.

93. Glennon, R. A. Discriminative stimulus properties of phenylisopropylamine derivatives. Drug and Alcohol Depend. 1986, 17, 119.

94. Glennon, R. A.; Titeler, M.; Young, R. A. Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol. Bull. 1986, 953-959.

95. Glennon, R. A.; Slusher, R. M.; Lyon, R. A.; Titeler, M.; McKenney, J. D. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J. Med. Chem. 1986, 29, 2375-2380.

96. Young, R.; Rosecrans, J. A.; Glennon, R. A.; Further studies on the dose-dependent stimulus sroperties of 5-methoxy-N,N-dimethyltryptamine. Pharmacol. Biochem. Behav. 1986, 25, 1207-1210.

97. Rasmussen, K.; Glennon, R. A.; Aghajanian, G. K.; Phenethylalamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity Eur. J. Pharmacol. 1986, 132, 79-82.

98. Glennon, R. A. Central serotonin receptors as targets for drug research. J. Med. Chem. 1987, 30, 1-12.

99. Glennon, R. A.; Little, P. J.; Rosecrans, J. R.; Yousif, M. Y. The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice. Pharmacol. Biochem. Behav. 1987, 26, 425.

100. Glennon, R. A.; Titeler, M.; Seggel, M. R.; Lyon, R. A. N-Methyl derivatives of the 5-HT2 antagonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med. Chem. 1987, 30, 930-932.

101. Glennon, R. A.; Yousif, M. Y.; Naiman, N.; Kalix, P. Methcathinone: A new and potent amphetamine-like agent. Pharmacol. Biochem. Behav. 1987, 26, 547-551.

102. Kerdawy, M.; Bayomi, S.; Shehata, I; Glennon, R. A. Condensed 1,2,3-triazines: 1,3,4- Thiadiazolo[3,2-a]-1,3, 5-triazines and isoxazolo[2,3-a]-1,3,5-triazines. J. Heterocyclic Chem. 1987, 24, 501-504.

103. Rosecrans, J. A.; Glennon, R. A. The effect of MDA and MDMA ("Ecstasy") isomers in combination with pirenperone on operant responding in mice. Pharmacol. Biochem. Behav. 1987, 28, 39-42.

104. Shehata, I.; Glennon, R. A. Mesoionic isoxazolo[2,3-a]pyrimidindiones and 1,3,4-oxadiazolo[3,2-a] pyrimidindiones as potential adenosine antagonists. J. Heterocyclic Chem. 1987, 24, 1291-1295.

105. Seggel, M. R.; Qureshi, G. D.; Glennon, R. A. Effect of 5-HT2-selective agonists on cat platelet aggregation. Life Sci. 1987, 1077-1081.

106. Titeler, M.; Lyon, R. A.; Davis, K. H.; Glennon, R. A. Selectivity of serotonergic drugs for multiple brain 5-HT receptors: Role of [3H]DOB, a 5-HT2 agonist radioligand. Biochem. Pharmacol. 1987, 36, 3265-3271.

107. Young, R.; Glennon, R. A.; Dewey, W. L.; Effects of pyrazolopyridines and a triazolopyridazine on the pentobarbital discriminative stimulus. Psychopharmacology, 1987, 93, 494-497.

108. Young, R.; Glennon, R. A.; Stimulus properties of benzodiazepines: Correlations with binding affinities, therapeutic potencies, and structure-activity relationships. Psychopharmacology, 1987, 93, 529-533.

109. Glennon, R. A.; Seggel, M. R.; Soine, W. H.; Lyon, R. A. Davis, K.; Titeler, M. [125I]-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane: An iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. J. Med. Chem. 1988, 31, 5-7.

110. Titeler, M.; Lyon, R. A.; Glennon, R. A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology, 1988, 94, 213-216.

111. Lyon, R. A.; Titeler, M.; Seggel, M. R.; Glennon, R. A. Indolealkylamine analogs share 5-HT2 binding characteristics with phenalkylamine hallucinogens. Eur. J. Pharmacol. 1988, 145, 291-296.

112. Glennon, R. A.; Pierson, M. E.; McKenney, J. D. Stimulus generalization of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) to propranolol, pindolol, and mesulergine. Pharm. Biochem. Behav. 1988, 29, 197-199.

113. Glennon, R. A.; Yousif, M.; Patrick, G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol. Biochem. Behav. 1988, 29, 443-449.

114. Glennon, R.A.; Titeler, M.; Lyon, R.A.; Slusher, R.M. N,N-Di-n-propylserotonin: Binding at serotonin sites and a comparison with 8-hydroxy-2-(di-n-propylamino)tetralin. J. Med. Chem. 1988, 31, 867-869.

115. Kalix, P.; Yousif, M. Y.; Glennon, R. A. Differential effect of the enantiomers of methylenedioxyamphetamine (MDMA) on the release of radioactivity from [3H]dopamine-prelabeled rat striatum. Res. Commun. Substance Abuse 1988, 9, 45-51.

116. Glennon, R. A.; Titeler, M.; Lyon, R. A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: A potential drug of abuse. Pharmacol. Biochem. Behav. 1988, 30, 597-601.

117. Glennon, R. A.; Naiman, N. A.; Lyon, R. A.; Titeler, M. Arylpiperazine derivatives as high-affinity serotonin 5-HT1A ligands. J. Med. Chem. 1988, 31, 1968-1971.

118. Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Titeler, M.; Lyon, R. A. NAN-190: An arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Eur. J. Pharmacol. 1988, 154, 339-341.

119. Glennon, R. A.; Ismaiel, A. M.; Martin, B.; Poff, D.; Sutton, M. A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine. Pharmacol. Biochem. Behav. 1988, 31, 9-13.

120. Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Titeler, M.; Lyon, R. A.; Herndon, J. L.; Misenheimer, B. Stimulus properties of arylpiperazines: NAN-190, a potential 5-HT1A serotonin antagonist. Drug Dev. Res. 1989, 16, 335-343.

121. Naiman, N. A.; Lyon, R. A.; Bullock, A. E.; Rydeleck, L. T.; Titeler, M.; Glennon, R. A. 2-(Alkylamino)tetralin derivatives: Interaction with 5-HT1A serotonin binding sites. J. Med. Chem. 1989, 32, 253-256.

122. Pierson, M. E.; Lyon, R. A.; Titeler, M.; Kowalski, P.; Glennon, R. A. Design and synthesis of propranolol analogues as serotonergic agents. J. Med. Chem. 1989, 32, 859-863.

123. Fitzgerald, R. L.; Blanke, R. V.; Rosecrans, J. A.; Glennon, R. A. Stereochemistry of the metabolism of MDMA to MDA. Life Sci. 1989, 45, 295-301.

124. Sadzot, B.; Baraban, J. M.; Glennon, R. A.; Lyon, R. A.; Leonhardt, S.; Jan, C-R.; Titeler, M. Hallucinogenic drug interactions at human brain 5-HT2 receptors: Implications for treating LSD induced hallucinogenesis. Psychopharmacology, 1989, 98, 495-499.

125. Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Smith, J. D.; Ismaiel, A. M.; Titeler, M.; Lyon, R. A. N-(Phthalimidoalkyl) derivatives of serotonergic agents: A common interaction at 5-HT1A serotonin binding sites? J. Med. Chem. 32, 1921-1926.

126. Glennon, R. A.; Misenheimer, B. Stimulus effects of N-mono ethyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav.1989, 33, 900-912.

127. Glennon, R. A.; Ismaiel, A. M.; McCarthy, B. G.; Peroutka, S. J. Binding of arylpiperazines to 5-HT3 serotonin receptors: Results of a structure-affinity study. Eur. J. Pharmacol. 1989, 168, 387-392.

128. Ismaiel, A. M.; Titeler, M.; Glennon, R. A. Gamma-carboline derivatives as potential serotonergic agents. Mansoura J. Pharm. (Egypt) 1989, 6, 1-13.

129. Fitzgerald, R. L.; Blanke, R. V.; Glennon, R. A.; Yousif, M.; Rosecrans, J. A.; Poklis, A. Determination of 3,4-methylenedioxyamphetamine (MDA) and N-methyl-3,4-methylenedioxyamphetamine (MDMA) enantiomers in whole blood. J. Chromatog. 1989, 490, 59-69.

130. Ismaiel, A. M.; Titeler, M.; Miller, K. J.; Smith, T. S.; Glennon, R. A. 5-HT1 and 5-HT2 binding profiles of the serotonergic agents a-methylserotonin and 2-methylserotonin J. Med. Chem. 1990, 33, 755-758.

131. Glennon, R. A. Serotonin receptors: Clinical Implications. Neurosci. Biobehav. Rev., 1990, 14, 35-47.

132. Kerdawy, M. M.; Ismaiel, A. M.; Gineinah, M.; Glennon, R. A. A convenient synthesis of 3-aryl-1,2,4-triazolo [4,3-c]quinazolines. J. Heterocyclic Chem, 1990, 27, 497-501.

133. Seggel, M. R.; Yousif, M. Y.; Lyon, R. A.; Titeler, M.; Roth, B. L.; Suba, E. A.; Glennon, R. A. An SAR study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J. Med. Chem., 1990, 33, 1032-1036.

134. Gineinah, M.; Ismaiel, A. M.; Kerdawy, M.; Glennon, R. A. Mesoionic 1,2,4-triazolo[4,3-c]quinazolines. J. Heterocyclic Chem., 1990, 27, 723-726.

135. Glennon, R. A., Misenheimer, B. Stimulus properties of a new designer drug: 4-Methylaminorex ("U4Euh"). Pharmacol. Biochem. Behav. 1990, 35, 517-521.

136. Darmani, N., Martin, B. R., Pandey, U, Glennon, R. A. Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav. 1990, 36, 901-906.

137. Higgs, R., Glennon, R. A. Stimulus properties of ring-methyl amphetamine analogs. Pharmacol. Biochem. Behav. 1990, 37, 835-837.

138. Glennon, R. A., Chaurasia, C., Titeler, M. Binding of indolylalkylamines at 5-HT2 sites: Examination of a hydrophobic binding region. J. Med. Chem. 1990, 33, 2777-2784.

139. Glennon, R. A., Raghupathi, R. K. Serotonin receptor ligands. Current CNS Patents 1990, 1, 323-343.

140. Glennon, R. A., Battaglia, G., Smith, J. D. (-)PPAP: A new selective ligand for sigma binding sites. Pharmacol. Biochem. Behav. 1990, 37, 557-559.

141 Darmani, N.A., Martin, B.R., Glennon, R.A. Withdrawal from chronic treatment with (±)DOI causes both sub- and supersensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur. J. Pharmacol. 1990, 186, 115-118.

142. Darmani, N. A. , Martin, B. R., Pandey, U., Glennon, R. A. Pharmacological classification of ear-scratch response in mice as a behavioral model for selective 5-HT2 receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions. Pharmacol. Biochem. Behav. 1990, 37, 95-99.

143. Rydelek-Fitzgerald, L., Teitler, M., Ismaiel, A. M., Glennon, R. A. NAN-190: Agonist and antagonist interactions with brain 5-HT1A receptors. Brain Res. 1990.

144. Yousif, M. Y., Fitzgerald, R. L., Narasimhachari, N. Rosecrans, J. A., Glennon, R.A Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. Drug Alcohol Depend. 1990, 26, 127-135.

145. Appel, N. M., Mitchell, W. M., Garlick, R. K., Glennon, R. A. Teitler, M., De Souza, E. B. Autoradiographic characterization of (±)-1-(2,5,-dimethoxy-4- [125I]iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1C receptors in rat brain. J. Pharmacol. Exp. Ther. 1990, 255, 843-857.

146. Glennon, R. A. Do hallucinogens act as 5-HT2 agonists? Neuropsychopharmacology 1990, 3, 509-517.

147. Glennon, R. A., DeVry, J., Spencer, D. G., Glaser, T. Stimulus properties of tiflucarbine: A novel antidepressant agent. Pharmacol. Biochem. Behav. 1990.

148. Glennon, R. A., Smith, J. D., Ismaiel, A. M., El-Ashmawy, M., Battaglia, G., Fischer, J.B Identification and exploitation of the sigma opiate pharmacophore. J. Med. Chem. 1991, 34, 1094-1098.

149. Darmani, N., Martin, B. B., Pandey, U., Glennon, R. A. Inhibition of 5-HT2-mediated head-twitch response by cocaine via indirect stimulation of adrenergic alpha-2 and serotonergic 5-HT1A receptors. Pharmacol. Biochem. Behav. 1991, 38, 353-357.

150. Glennon, R.A. Serotonin receptors and site-selective agents. J. Physiol. Pharmacol. (Poland) 1991, 1, 42-60.

151. Glennon, R. A., Ismaiel, A. M., Chaurasia, C., Titeler, M. 5-HT1D serotonin receptors: Results of a structure-affinity investigation. Drug Dev. Res. 1991, 22, 25-36.

152. Glennon, R.A., Ismaiel, A., Smith, J.D., Yousif, M.Y., El-Ashmawy, M., Herndon, J.L., Fischer, J.B., Burke Howie, K.J., Server, A.A. Binding of substituted and conformationally restricted derivatives of N-(3-phenyl-n-propyl)- 1-phenyl-2-aminopropane at s receptors. J. Med. Chem. 1991, 34, 1855-1859.

153. Glennon, R.A., El-Ashmawy, M., Ismaiel, A.M., Fischer, J.B. Binding of N-substituted 2-phenylaminoethanes to s and serotonin 5-HT1A receptors. Med. Chem. Res. 1991, 1, 109-114.

154. Raghupathi, R.K., Rydelek-Fitzgerald, L., Teitler, M., Glennon, R.A. Analogues of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimidio)-butyl]piperazine with reduced a1-adrenergic affinity. J. Med. Chem. 1991, 34, 2633-2638.

155. Glennon, R.A., Bartyzel, P., Teitler, M. Binding of benz[e]-and benz[g]-fused tryptamine derivatives at serotonin receptors: Evidence for a region of bulk tolerance. Med. Chem. Res. 1991, 1, 201-206.

156. Glennon, R.A., El-Ashmawy, M., Fischer, J.B., Burke Howie, K.J., Ismaiel, A.M. N-Substituted 5-phenyl pentylamines: A new class of s receptor ligands. Med. Chem. Res. 1991, 1, 207-212.

157. Glennon, R. A.; Darmani, N.; Martin, W. Modulation of the behavioral effects of serotonergic agents by multiple 5-HT receptors Life Sci. 1991, 48, 2493-2498.

158. Glennon, R.A.; Dukat, M. Serotonin Receptors and their Ligands: A lack of selective agents. Pharmacol. Biochem. Behav. 1991, 40, 1009-1017.

159. Glennon, R.A.; Yousif, M.Y.; Ismaiel, A.M.; El-Ashmawy, M.B.; Herndon, J.L.; Fischer, J.B.; Server, A.C.; Burke-Howie, K.J. Novel 1-phenylpiperazines and 4-phenylpiperidines as high-affinity sigma ligands. J. Med. Chem. 1991, 34, 3360-3365.

160. Dukat, M.; Miller, K.; Teitler, M.; Glennon, R.A. Binding of amine-substituted and quaternary amine analogs of serotonin at 5-HT3 serotonin receptors. Med. Chem. Res. 1991, 1, 271-276.

161. Bakthavachalam, V.; Fell, B.; Teitler, M.; Glennon, R.A.; Neumeyer, J.L. Fluorescent probes for serotonin 5-HT1A receptors: Synthesis, receptor affinity and selectivity. Med. Chem. Res. 1991, 1, 265-270.

162. Westkaemper, R.B.; Glennon, R.A. Approaches to molecular modeling studies and specific application to serotonin ligands and receptors. Pharmacol. Biochem. Behav. 1991, 40, 1019-1031.

163. Westkaemper, R.B.; Dukat, M.; Glennon, R.A. Molecular modeling of drug-receptor interactions using a 5-HT2 receptor model. Med. Chem. Res. 1991, 1, 401-408.

164. Ablordeppey, S.Y.; El-Ashmawy, M.B.; Glennon, R.A. Analysis of the structure-activity relationships of sigma receptor ligands. Med. Chem. Res. 1991, 1, 425-438.

165. Glennon, R.A. Preface for special serotonin issue of Pharmacol. Biochem. Behav. 1991, 40, 1007.

166. Glennon, R.A.; Raghupathi, R.; Bartyzel, P.; Teitler, M.; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: Evidence for a Lack of selectivity. J. Med. Chem. 1992, 35, 734-740.

167. Glennon, R.A.; Young, R.; Dukat, M. The 5-HT3 agonist 2-methylserotonin as a training drug in drug discrimination studies. Pharmacol. Biochem. Behav. 1992, 41, 361-364.

168. El-Bermawy, M.; Raghupathi, R.; Ingher, S.P.; Teitler, M.; Maayani, S.; Glennon, R.A. 4-[4-(1-Noradamantane carboxamido)butyl]-1-(2-methoxyphenyl) piperazine: A high affinity 5-HT1A-selective agent. Med. Chem. Res. 1992, 2, 88-95.

169. El-Ashmawy, M.; Ablordeppey, S.Y.; Issa, H.; Gad, L.; Fischer, J.B.; Burke Howie, K.J.;Glennon, R.A. Further investigation of 5-phenylpentylamine derivatives as novel sigma receptor ligands. Med. Chem. Res. 1992, 2, 119-126.

170. El-Bermawy, M.; Lotter, H.; Glennon, R.A. Comparative molecular field analysis of the binding of arylpiperazines at 5-HT1A serotonin receptors. Med. Chem. Res. 1992, 2, 290-297.

171. Ablordeppey, S.Y.; El-Ashmawy, M.B.; Glennon, R.A. Analysis of the structure-activity relationships of sigma receptor ligands. Med. Chem. Res. 1992, 2, 425-438.

172. Herndon, J.L.; Pierson, M.E.; Glennon, R.A. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol. Biochem. Behav. 1992, 43, 739-748.

173. Glennon, R.A.; Higgs, R. Investigation of MDMA-related agents in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 1992, 43, 759-763.

174. Glennon, R.A. Concepts for design of 5-HT1A serotonin agonists and antagonists. Drug Dev. Res. 1992, 26, 251-274.

175. Ablordeppey, S.Y.; Fischer, J.B.; Burke Howie, K.J.; Glennon, R.A. Design, synthesis and binding of sigma receptor ligands derived from butaclamol. Med. Chem. Res. 1992, 2, 368-375.

176. Herndon, J.L.; Ismaiel, A.; Ingher, S.; Teitler, M.; Glennon, R.A. Ketanserin analogues: Structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J. Med. Chem. 1992, 35, 4903-4910.

177. Glennon, R.A.; Higgs, R.; Young, R.; Issa, H. Further studies on N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: Antagonism by 5-hydroxytrptamine antagonists. Pharmacol. Biochem. Behav. 1992, 43, 099-1106.

178. Westkaemper, R.B.; Yousif, M.; Teitler, M.; Glennon, R.A. Binding of aporphines at 5-HT1A serotonin receptors: A computational investigation of potential binding modes. Med. Chem. Res. 1992, 2, 482-490.

179. Glennon, R.A.; Dukat, M. 5-HT receptor ligands: Update 1992. Current Drugs, 1992, 1, 1-45.

180. Young, R.; Glennon, R.A. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus. Eur. J. Pharmacol. 1992, 212, 117-119.

181. Glennon, R.A.; Maarouf, R.; Fahmy, S.; Martin, B.; Fan, F.; Yousif, M.; Shafik, R.; Dukat, M. Structure-affinity relationships of simple nicotine analogs. Med. Chem. es. 1993, 2, 546-551.

182. Young, R.; Glennon, R.A. Cocaine-stimulus generalization to two new designer drugs: Methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav. 1993, 45, 229-231.

183. Young, R.; Herndon, J.L. Antagonism of a (+)N-allylnormetazocine stimulus by (-)PPAP and several structurally related analogs. Pharmacol. Biochem. Behav. 1993, 45, 865-869.

184. Ablordeppey, S.Y.; Issa, H.; Fischer, J.B.; Burke Howie, K.J.; Glennon, R.A. Synthesis and structure-affinity relationship studies of sigma ligands related to haloperidol. Med. Chem. Res. 1993, 3, 131-138.

185. Ismaiel, A.M.; De Los Angeles, J.; Teitler, M.; Ingher, S.; Glennon, R.A. Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2 aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist. J. Med. Chem. 1993, 36, 2519-2525.

186. Glennon, R.A. MDMA-like stimulus effects of a-ethyltryptamine and the a-ethyl homolog of DOM. Pharmacol. Biochem. Behav. 1993, 46, 459-462.

187. Westkaemper, R.B. and Glennon, R.A. Molecular graphics models of members of the 5-HT2 subfamily: 5-HT2A, 5-HT2B, and 5-HT2C receptors. Med. Chem. Res. 1993, 3, 317-334.

188. Abou-Gharbia, M.; Ablordeppey, S.Y.; Glennon, R.A. Sigma receptors and their ligands: The Sigma Enigma. Annual Reports in Medicinal Chemistry. 1993, 28, 1-10.

189. Glennon, R.A., Westkaemper, R.B. 5-HT1D Receptors: A serotonin receptor population for the 1990s. Drug News Perspect. 1993, 6, 390-405.

190. Dukat, M.; Damaj, M.I.; Glassco, W.; Dumas, D.; May, E.L.; Martin, B.R.; Glennon, R.A. Epibatidine: A very high affinity nicotine-receptor ligand. Med. Chem. Res. 1994, 4, 131-139.

191. Damaj, M.I.; Glennon, R.A.; Martin, B.R. Involvement of the serotonergic system in the hypoactive and antinociceptive effects of nicotine in mice. Brain Res. 1994, 33, 199-203.

192. Glennon, R. A.; Ablordeppey, S. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; Fischer, J. B.; and Burke-Howie, K. Structural features important sigma-1 (s-1) receptor binding. J. Med. Chem. 1994, 37, 1214-1219.

193. Carroll, F.I.; Glennon, R.A.; Johnson, M.R.; Teitler, M.; Zimmerman, D.M. Hallucinogenic Agents: Drugs of abuse as neurochemical tools. NIDA Res. Mono. 1994, 140, 94-98.

194. Glennon, R.A.; Dukat, M.; El-Bermawy, M.; Law, H.; De Los Angeles, J.; Teitler, M.; King, A.; Herrick-Davis, K. Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines. J. Med. Chem. 1994, 37, 1929-1935

195. Dukat, M.; Herrick-Davis, K.; Teitler, M.; Glennon, R.A. Piperidine derivatives of serotonin as selective 5-HT1A serotonin receptor agonists. Med.Chem.Res. 1994, 4, 254-258.

196. Glennon, R.A.; Hong, S-S.; Dukat, M.; Teitler, M. and Davis, K. 5-(Nonyloxy)tryptamine: A novel high-affinity 5-HT1Dß serotonin receptor agonist. J. Med. Chem. 1994, 37, 2828-2830.

197. Glennon, R.A.; Herndon, J.L.; Dukat, M. Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. 1994, 4:461-473.

198. Choudhary, M.S.; Sachs, N.; Ulver, A.; Glennon, R.A.; Westkaemper, R.B.; Roth, B.L. Differential ergoline and ergopeptine binding to 5-HT2A receptors: Ergolines require an aromatic residue at position 340 for high affinity. Mol. Pharmacol. 1995, 47: 450-457.

199. Ismaiel, A.M.; Aruda, K.; Teitler, M.; Glennon, R.A. Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding. J. Med. Chem. 1995, 38, 1196-1202.

200. Glennon, R.A.; Young, R.; Martin, B.; Dal Cason, T. Methcathinone ("CAT"): An enantiomeric potency comparison. Pharmacol. Biochem. Behav. 1995, 50, 601-601.

201. Hong, S.-S.; Dukat, M.; Teitler, M.; Herick-Davis, K.; McCallum, K.; Kamboj, R.; Glennon, R.A. Binding of 5-arylalkyloxytryptamines at human 5-HT1Dß serotonin receptors. Med. Chem. Res. 1995, 5:690-699.

202. Glennon, R.A.; Hong, S.-S.; Bondarev, M.; Law, H.; Dukat, M.; Rakhit, S.; Power, P.; Fan, E.; Kinneau, D.; Kamboj, R.; Teitler, M.; Herrick-Davis, K.; Smith. C. Binding of O-alkyl derivatives of serotonin at human 5-HT1Dß receptors. J. Med. Chem. 1996, 39, 314-322.

203. Glennon, R.A.; Dukat, M.; Westkaemper, R.B.; Ismaiel, A.M.; Izzarelli, D.G.; Parker, E.M. The binding of propranolol at 5-hydroxytryptamine1Dß T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. Mol. Pharm. 1996, 49, 198-206.

204. Young, R.; Glennon, R.A. A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA. J. Pharmacol. Exp. Ther. 1996, 276, 594-601.

205. Ismaiel, A.M. Dukat, M., Nelson, D.L. Lucaites, V.L.; Glennon, R.A. Binding of N2-substituted pyrido[4,3-b]indole analogs of spiperone at human 5-HT2A, 5-HT2B, and 5-HT2C serotonin receptors. Med. Chem. Res. 1996, 6, 197-211.

206. Glennon, R.A.; Fiedler, W.; Dukat, M.; Damaj, I.; Martin, B. Pyrrolidine-modified analogues of nicotine: a structure-affinity investigation. Eur. J. Med. Chem.1996, in press.

207. Glennon, R. A.; Young, R.; Dukat, M.; Cheng, Y. Initial characterization of PMMA as a discriminative stimulus. Pharmacol. Biochem. Behav. 1996, in press.

208. Young, R. A.; Glennon, R. A. Cocaine-stimulus generalization to MDA optical isomers: A re-evaluation. Pharmacol. Biochem. Behav. 1996, in press.

209. Iwamura, T.; Casey, C. T.; Young, R.; Dukat, M.; Teitler, M.; Fadden, J. S. P.; Glennon, R. A. 4-(6-Fluorobenzisoxazol-3-yl)piperidine, a risperidone metabolite with serotonergic activity of potential clinical significance. Med. Chem. Res. 1996, in press.

210. Young, R.; Darmani, N. A.; Elder, E. L.; Dumas, D.; Glennon, R. A. Clobenzorex: Evidence for amphetamine-like behavioral actions. Pharmacol. Biochem. Behav. 1996, in press.

211. Glennon, R. A.; Dukat, M. Nicotine receptor ligands. Med. Chem. Res. 1996, in press.

212. Dukat, M.; Abdel-Rahman, A. A.; Ismaiel, A. M.; Ingher, S.; Teitler, M.; Gyermek, L.; Glennon, R. A. Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. J. Med. Chem. 1996, 39, 20, 4017-4026.

213. Malmusi, L.; Dukat, M.; Young, R.; Teitler, M.; Darmani, N.A.; Ahmad, B.; Smith, C.; and Glennon, R.A. 1,2,3,4-Tetrahydroisoquinoline and related analogs of the phenylalkylamine designer drug MDMA. Med. Chem. Res., 1996, 412-426.

214. Malmusi, L.; Dukat, M.; Young, R.; Teitler, M.; Darmani, N.A.; Ahmad, B.; Smith C.; and Glennon, R.A.. 1,2,3,4-Tetrahydroisoquinoline analogs of phenylalkylamine stimulants and hallucinogens. Med. Chem. Res., 1996, 400-411.

Book Chapters

1. Glennon, R. A.; Rosecrans, J. A.; Young, R. The use of the drug discrimination paradigm for studying hallucinogenic agents. In: Drug Discrimination: Applications in CNS Pharmacology, F. C. Colpaert and J. L. Slangen eds., Elsevier Biomedical Press, Amsterdam, 1982. pp 69-96.

2. Glennon, R. A. Hallucinogenic Phenylisopropylamines: Stereochemical Aspects. In: Stereoisomers: Drugs in Psychopharmacology, D. Smith ed., CRC Press, Boca Raton, 1983. pp 327-370.

3. Nichols, D. E.; Glennon, R. A. Medicinal Chemistry and Structure-Activity Relationships of Hallucinogenic Agents. In: Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives, B. Jacobs ed., Raven Press, NY 1984. pp 95-142.

4. Glennon, R. A. Interaction of hallucinogenic agents with serotonin receptors. In: Medicinal Chemistry, R. Dahldom and J. L. G. Nilsson, eds., Swedish Pharmaceutical Press, Stockholm 1985. pp 116-129.

5. Glennon, R. A. The role of serotonin in the mechanism of action of hallucinogenic agents. In: Neuropharmacology of Serotonin, A. R. Green, ed., Oxford University Press, 1985.

6. Arvidsson, L. E.; Hacksell, U.; Glennon, R. A. Recent advanc-es in central 5-hydroxytryptamine receptor agonists and an-tagonists. In: Progress in Drug Research, E. Jucker, ed., Birkhauser Verlag, Basel, 1986. pp 365-471.

7. Glennon, R. A. Discriminative stimulus properties of site-selective serotonin agonists. In: Transduction Mechanisms of Drug Stimuli, F. C. Colpaert and R. L. Balster eds., Springer Verlag, Berlin, 1988. pp 15-32.

8. Glennon, R. A.; Young, R. Use of the drug discrimination paradigm for investigating structure-activity relationships, in Drug Dependence, M. Bozarth ed., Springer-Verlag, NY, 1987. pp 373-390.

9. Glennon, R. A. Psychoactive Phenylisopropylamines. In: Psychopharmacology, Third Generation of Progress, H. Meltzer ed., Raven Press, 1987. pp 1627-1634.

10. Young, R.; Glennon, R. A. Second generation anxiolytics and serotonin, In: Serotonin:Behavioral Pharmacology, R. H. Rech and G. A. Gudelsky eds. NPP Press, Ann Arbor MI, 1988. pp 239-258.

11. Glennon, R. A.; Lucki, I. Behavioral aspects of serotonin agonists", In: Serotonin Receptors, E. Sanders-Bush ed., Humana Press, NJ, 1988. pp 253-294.

12. Glennon, R. A. Central serotonin receptors, In: Receptor Pharmacology and Function, M. Williams, R. A. Glennon and P. Timmermans eds., M. Dekker, 1989. pp 257-292.

13. Glennon, R. A.; Young, R.; Pierson, M. E. Stimulus properties of arylpiperazine second generation anxiolytics. In: The Behavioral Pharmacology of 5-HT, P. Bevan, A. R. Cools, and T. Archer, eds. Lawrence Earlbaum Associates, NY, 1989. pp 445-449.

14. Glennon, R. A.; Seggel, M. R. Interaction of phenylisopropylamines with 5-HT2 receptors: A QSAR analysis. in Bioactive Mechanisms, Magee, P. S. ed. ACS Press, Washinton DC, 1989.

15. Glennon, R. A. Synthesis and evaluation of amphetamine analogs: A review. In: Clandestinely Produced Drugs, Analogues, and Precursors, M. Klein, F. Sapienza, H. McClain and I. Khan, eds. US Government Printing Office, Washington DC, 1989. pp 39-65.

16. Glennon, R. A. "Stimulus Properties of Hallucinogenic Phenalkylamines and Related Designer Drugs: Formulation of Structure-Activity Relationships" In: Pharmacology and Toxicology of Amphetamine and Related Designer Drugs, Ashgar, R. DeSouza, E. eds., U.S. Government Printing Office, Washington, DC., 1989 pp 43-67.

17. Teitler, M.; Leonhardt, S.; Appel, N. M.; DeSouza, E. B.; Glennon, R. A. "Receptor pharmacology of MDMA and related hallucinogens" In: The Neuropharmacology of Serotonin, Peroutka, S., ed., New York Academy of Science, New York, 1990. pp. 626-638.

18. Glennon, R. A., Westkaemper, R., Bartyzel, P. "Medicinal Chemistry of Serotonergic Agents" In: Serotonin Receptor Subtypes Peroutka, S. ed., Wiley-Liss, NY, 1991. pp. 19-64.

19. Glennon, R. A. Serotonergic agents and CNS receptors, in Advances in CNS Drug-Receptor Interactions, J. Cannon, ed. JAI Press, Greenwich. 1991.

20. Glennon, R. A., Tejani, S. "Mesoionic Nucleosides and Heterobases" In: Chemistry of Nucleosides and Nucleotides, L. Townsend, ed., Plenum Press, 1991. pp. 1-21.

21. Glennon, R.A., Peroutka, S.J., Dukat, M. "Binding characteristics of a quaternary amine analog of serotonin: 5-HTQ", In: Serotonin: Molecular Biology, Receptors and Functional Effects, J. R. Fozard and P. R. Saxena, eds., Birkhauser-Verlag, Basel, 1991. pp. 186-191.

22. Glennon, R. A. "Animal Models for Assessing Hallucinogenic Agents" In: Animal Models for Assessing Hallucinogenic Agents, Boulton, A.; Baker, G.; Wu, P.; ed., Humana Press, Clifton, New Jersey, 1992. pp. 345-381.

23. Glennon, R.A. "Discriminative Stimulus Properties of Hallucinogens and Related Designer Drugs" In: Drug Discrimination: Application in Drug Abuse Research, NIDA Research Monograph, R.A. Glennon, T. Jarbe and J. Frankenhein, eds., Washington DC, 1991. pp. 25-44.

24. Glennon, R.A. "Phenalkylamine Stimulants, Hallucinogens and Designer Drugs" In: Proceedings of the 1990 CPDD Meeting, L.S. Harris, ed., Washington DC, 1990. pp. 154-160.

25. Glennon, R.A.; Westkaemper, R.B. "Serotonin Receptors, 5-HT Ligands and Receptor Modeling" In: Trends in Receptor Research, P. Angeli, U. Gulini and W. Quaglia, eds, Elsevier, Amsterdam, 1992. pp. 185-207.

26. Glennon, R.A. Classification of agents used in serotonin research. In: Serotonin, P. M. Vanhoutte, P. R. Saxena, R. Paoletti, N. Brunello, A. S. Jackson, eds., Kluwer Academic Publishers, Dordrecht, 1993. pp 49-54.

27. Glennon, R.A. "Classical hallucinogens, an introductory overview". In: Hallucinogens: An Update. G.C. Lin and R.A. Glennon, eds., U.S. Government Printing Office, Washington, D.C. 1994. pp. 4-32.

28. Westkaemper, R.B.; Glennon, R.A. "Molecular modeling of the interaction of LSD and other hallucinogens with 5-HT2 receptors". In: Hallucinogens: An Update. G. C. Lin and R.A. Glennon, eds., U. S. Government Printing Office, Washington, D.C. 1994. pp. 263-283.

29. Herndon, J.L.; Glennon, R.A. Serotonin receptors, agents, and actions. In: Drug Design for Neuroscience, A.P. Kozikowski, ed. Raven Press, NY, 1993. pp 167-212.

30. Glennon, R.A.; Dukat, M. "Serotonin Receptor Subtypes". In: Psychopharmacology: The fourth generation of progress. Bloom, R.E.; Kupfer, D.J.; Raven Press 1994, 415-429.

31. Glennon, R.A. How do LSD and LSD-related hallucinogens work? In: Hallucinogens, LSD, and Raves. Proceedings of the Scientific Advisory Board of the American Council for Drug Education, American Council for Drug Education, Washington, D. C. 1994. pp 14-20.

32. Glennon, R.A.; Dukat, M. Serotonin Subfamily of receptors. In: The RBI Handbook of Receptor Classification. J.W. Kebabian and J.L. Neumeyer, eds., Research Biochemicals International, Natick, 1994. pp. 58-61..

33. Glennon, R.A. Sigma receptors. In: The RBI Handbook of Receptor Classification. J. W. Kebabian and J. L. Neumeyer, eds., Research Biochemicals International, Natick, 1994. pp 62-63.

34. Dukat, M.; Damaj, M.I.; Dumas, D.; Glassco, W.; May, E.L.; Martin, B.R.; Glennon, R.A. "Epibatidine". In: Effects of Nicotine on biological systems II (APS). P.B.S. Clarke, M. Quik, K. Thurau, F. Adlkofer, eds., Birkhauser, Basel, Switzerland, 1995.

35. Glennon, R.A. "Classical Hallucinogens". In: Handbook of Experimental Pharmacology: Pharmacological Aspects of Drug Dependence. C. R. Schuster and M. J. Kuhar, eds., Springer Verlag, Basel, 1996. pp 343-371.

36. Glennon, R.A.; Dukat, M. Serotonin receptors and ligands. In: Introduction to the Principles of Drug Design and Action H. J. Smith, ed. in press.

Books Edited

1. Receptor Pharmacology and Function, M. Williams, R. A. Glennon and P. Timmermans eds., M. Dekker, New York, 1989.

2. Drug Discrimination: Applications in Drug Abuse Research, R. A. Glennon, T. Jarbe and J Frankenheim, U.S. Government Printing Office, Washington DC, 1991.

3. Hallucinogens: An Update, G.C. Lin and R.A. Glennon, eds, U.S. Government Printing Office, Washington, D.C. 1994.

PATENTS

1. Glennon, R. A. Tryptamine analogs with 5-HT1D selectivity. US Patent 5,496,957 (March 5, 1996).

2. Glennon, R. A. 5-HT1D receptor ligands. US Patent 5,504,101 (April 2, 1996).